CytomX Therapeutics, Inc. Earnings Recaps
Q1 2026
May 8, 2026
Shares dropped 3.6% following the earnings release, primarily due to cautious outlook and ongoing dose optimization challenges with Varseta-M. Investors responded negatively to the tentative guidance and need for further clinical dose refinement, tempering enthusiasm despite promising early data.
Key takeaways
- Market reaction of -3.6% reflects investor concerns about the pace of clinical development and lack of clear near-term approval catalyst.
- Varseta-M showed encouraging Phase I efficacy in late-line colorectal cancer with confirmed ORR between 20-32% and median PFS around 7 months.
- Dose optimization ongoing with 40 patients enrolled in latest cohorts; final dose selection delayed until potentially late 2026 or early 2027.
- Safety remains a key focus with updated management strategies aimed at reducing high-grade diarrhea, Varseta-M’s principal adverse event.
- Combination studies with bevacizumab initiated to support earlier-line use, but data for these will not be available until next year, contributing to cautious outlook.
Q3 2025
Nov 8, 2025
CytomX Therapeutics reported robust progress in its third quarter 2025 results, with encouraging interim Phase I data for its colorectal cancer drug candidate, CX-2051, demonstrating significant clinical activity and a well-tolerated safety profile.
Key takeaways
- CX-2051, targeting EpCAM in colorectal cancer, showed meaningful tumor reductions and a promising median progression-free survival of 5.8 months.
- The drug was generally well tolerated, with no significant safety issues, implying effective use of CytomX's proprietary masking technology.
- The company aims to expand the Phase I study to about 100 patients and initiate a Phase Ib study with bevacizumab in Q1 2026, enhancing treatment potential.
- A strategic addition to the team, Rachael Lester as Chief Business Officer, is expected to bolster corporate development efforts.
- CytomX remains committed to addressing unmet needs in oncology, with ambitions to establish CX-2051 as a new standard of care in late-stage colorectal cancer.